FINWIRES · TerminalLIVE
FINWIRES

Paradigm Biopharmaceuticals完成1,400萬澳元股票配售;股價下跌16%

By

-- 根據週一提交給澳洲證券交易所的文件顯示,Paradigm Biopharmaceuticals(ASX:PAR)已完成一項1,400萬澳元的股票配售,面向機構投資者和成熟投資者。由於市場需求旺盛,配售規模從最初的800萬澳幣目標上調。 該公司還啟動了一項符合條件的股東的股票購買計劃,旨在額外籌集至多200萬澳元。 此次配售中,該公司以每股0.19澳元的價格發行了約7,370萬股普通股。 此次融資將為該公司三期膝骨關節炎試驗的中期分析(預計將於第三季進行)提供資金彈性。 Paradigm Biopharmaceuticals的股價在周一的交易中下跌了近16%。

Related Articles

Asia

Dongjiang Environmental's Loss Widens 2.7% in Q1

Dongjiang Environmental (HKG:0895, SHE:002672) recorded an attributable loss of 150.2 million yuan in the first quarter of 2026, 2.7% wider than 146.3 million yuan a year prior, according to a Monday Hong Kong bourse filing.Loss per share widened to 0.14 yuan from 0.13 yuan in the corresponding period of the previous fiscal year.The waste disposal management company's revenue from operations declined 13% to 602.6 million yuan from 695.9 million yuan in the year-ago period.

$HKG:0895$SHE:002672
Sectors

Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday

Health care stocks were edging higher pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.2% and the iShares Biotechnology ETF (IBB) marginally advancing.Organon (OGN) has agreed to be acquired by Sun Pharmaceutical Industries for $14 per share in an all-cash deal with an $11.75 billion enterprise valuation, the companies said. Shares of Organon were up more than 17% premarket.Oruka Therapeutics (ORKA) stock was up more than 34% after the company said 63.5% of patients treated with ORKA-001 achieved the primary endpoint of complete skin clearance at week 16 in a phase 2a trial in moderate-to-severe plaque psoriasis.Ligand Pharmaceuticals (LGND) shares were up more than 3% after the company said it has agreed to purchase biotechnology peer Xoma Royalty (XOMA) in an all-cash deal valued at roughly $739 million.

$IBB$LGND$OGN$ORKA$XLV$XOMA
Asia

Zuoli Kechuang Logs Drop in Q1 Profit

Zuoli Kechuang Micro-finance Company (HKG:6866) recorded a decline in attributable profit in the first quarter of 2026 to 13.6 million yuan from 14.8 million yuan a year prior, according to a Monday Hong Kong bourse filing.Net interest income for the three months slipped to 28.4 million yuan from 35.2 million yuan in the year-ago period.

$HKG:6866